

# Development of highly potent melanogenesis inhibitor by in vitro, in vivo and computational studies

Qamar Abbas<sup>1</sup>  
Zaman Ashraf<sup>2</sup>  
Mubashir Hassan<sup>1</sup>  
Humaira Nadeem<sup>3</sup>  
Muhammad Latif<sup>4</sup>  
Samina Afzal<sup>5</sup>  
Sung-Yum Seo<sup>1</sup>

<sup>1</sup>Department of Biology, College of Natural Sciences, Kongju National University, Gongju, Republic of Korea; <sup>2</sup>Department of Chemistry, Allama Iqbal Open University, Islamabad, <sup>3</sup>Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan; <sup>4</sup>Center for Genetics and Inherited Diseases, Taibah University, Almadinah Almunawwarah, Kingdom of Saudi Arabia; <sup>5</sup>Faculty of Pharmacy, Bahauddin Zakria University, Multan, Pakistan

Correspondence: Sung-Yum Seo  
Department of Biology, College of Natural Sciences, Kongju National University, 56 Gongjudehak-Ro 56, Gongju, Chungnam 32588, Republic of Korea  
Tel +82 41 850 8503  
Fax +82 41 850 8503  
Email dnalove@kongju.ac.kr

Zaman Ashraf  
Department of Chemistry, Allama Iqbal Open University, Islamabad 44000, Pakistan  
Tel +92 32 1519 4461  
Fax +92 51 2891471  
Email mzchem@yahoo.com

**Abstract:** The present work describes the synthesis of few hydroxylated amide derivatives as melanogenesis inhibitors. In vitro, in vivo and computational studies proved that compound **6d** is a highly potent melanogenesis inhibitor compared to standard kojic acid. The title amides **4a–e** and **6a–e** were synthesized following simple reaction routes with excellent yields. Most of the synthesized compounds exhibited good mushroom tyrosinase inhibitory activity, but compound **6d** showed excellent activity ( $IC_{50}$  0.15  $\mu$ M) compared to standard kojic acid ( $IC_{50}$  16.69  $\mu$ M). Lineweaver–Burk plots were used for the determination of kinetic mechanism, and it was found that compounds **4c** and **6d** showed non-competitive inhibition while **6a** and **6b** showed mixed-type inhibition. The kinetic mechanism further revealed that compound **6d** formed irreversible complex with the target enzyme tyrosinase. The  $K_i$  values determined for compounds **4c**, **6a**, **6b** and **6d** are 0.188, 0.84, 2.20 and 0.217  $\mu$ M respectively. Results of human tyrosinase inhibitory activity in A375 human melanoma cells showed that compound **6d** exhibited 91.9% inhibitory activity at a concentration of 50  $\mu$ g/mL. In vivo cytotoxicity evaluation of compound **6d** in zebrafish embryos showed that it is non-toxic to zebrafish. Melanin depigmentation assay performed in zebrafish indicated that compound **6d** possessed greater potential in decreasing melanin contents compared to kojic acid at the same concentration. Computational studies also supported the wet lab findings as compound **6d** showed a highest binding affinity with the target protein (PDBID: 2Y9X) with a binding energy value of  $-7.90$  kcal/mol. Molecular dynamic simulation studies also proved that amide **6d** formed the most stable complex with tyrosinase. Based upon our in vitro, in vivo and computational studies, we propose that compound **6d** is a promising candidate for the development of safe cosmetic agent.

**Keywords:** melanogenesis, computational studies, tyrosinase inhibition, zebrafish, melanin quantification

## Introduction

Melanogenesis, the process of skin color formation, is controlled by a complex molecular regulatory network embedded in the keratinocytes and melanocytes, which results in the skin and hair pigmentation.<sup>1–3</sup> Melanin biosynthesis in melanosomes is regulated by a copper-containing metalloenzyme tyrosinase. Tyrosine in the presence of tyrosinase is converted into melanin through a series of biochemical reactions.<sup>4,5</sup> L-tyrosine and L-3,4-dihydroxyphenylalanine (L-DOPA) are the important substrates involved in melanin biosynthesis.<sup>6–8</sup> The presence of melanins in the surrounding keratinocytes is the important factor that determines the color of the human skin.<sup>9,10</sup>

Ultraviolet exposure,  $\alpha$ -melanocyte-stimulating hormone, melanocortin 1 receptor and agouti-related protein are some of the other factors involved in melanogenesis.<sup>11,12</sup>

Melanogenesis corresponds to a possible cellular danger and is confined to special melanosomes in melanocytes, which synthesize pigments and transfer them to recipient cells.<sup>13</sup> The abnormal proliferation of melanocytes results in melanoma, a type of skin cancer.<sup>14,15</sup> Melasma and post-inflammatory disorders are examples of hyperpigmentation disorders for which patients pursue treatment.<sup>16</sup>

Higher quantity of tyrosinase activity can also be linked to neurodegenerative diseases due to *o*-quinones formation by oxidation of dopamine results in neuronal damage and cell death.<sup>17–19</sup> The agents that are clinically used for hyperpigmentation disorders are usually associated with side effects. Therefore, there arises a need to develop some novel melanogenesis inhibitors with decreased side effects. A number of hydroxy-substituted aromatic acids and esters have been reported as potent melanogenesis inhibitors.<sup>20–23</sup> Takahashi and Miyazawa also reported the potential of hydroxylated amides and analogues to potentially inhibit melanogenesis.<sup>24</sup> The present work describes the synthesis of hydroxylated amides and their melanogenesis potency.

## Materials and methods

### Chemicals

2-amino-*p*-cymene, mushroom tyrosinase, L-DOPA and other required chemicals were purchased from Sigma-Aldrich, St Louis, MO, USA. Melting points were determined using a Digmelt MPA 160 melting point apparatus and are reported uncorrected. FTIR spectra were recorded using Shimadzu FTIR–8400S spectrometer (Kyoto, Japan;  $\nu$ ,  $\text{cm}^{-1}$ ).  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra ( $\text{DMSO}-d_6$ ) were recorded using a Bruker 400 MHz spectrometer (Brüker


Biospin, Switzerland). Chemical shifts ( $\delta$ ) were reported in parts per million (ppm) downfield from the internal standard tetramethylsilane. The purity of the compounds was checked by thin layer chromatography (TLC) on silica gel plate using *n*-hexane and ethyl acetate as mobile phase.

### Synthesis of 2-chloro-N-[2-methyl-5-(propan-2-yl)phenyl]acetamide (2)

2-amino-*p*-cymene **1** (0.01 mol) and triethylamine (0.01 mol) were reacted with chloroacetyl chloride (0.01 mol) in anhydrous dichloromethane (25 mL) at  $0^\circ\text{C}$  to  $-5^\circ\text{C}$ . The reaction mixture was stirred over a period of 1 h at constant temperature. The reaction mixture was then stirred at room temperature for further 5 h and progress of the reaction was determined by TLC. The mixture was washed with 5% HCl and 5% sodium hydroxide solution; the organic layer was washed with saturated aqueous NaCl, dried over anhydrous magnesium sulfate, filtered and the solvent was removed under reduced pressure. The crude 2-chloro-N-[2-methyl-5-(propan-2-yl)phenyl]acetamide **2** was recrystallized in ethanol as needle-like crystals: melting point  $94^\circ\text{C}$ – $96^\circ\text{C}$ ; yield 82%;  $R_f=0.54$  (*n*-hexane: ethyl acetate 2:1); FTIR  $\nu_{\text{max}}$   $\text{cm}^{-1}$ : 3,354 (N–H), 2,987 (sp<sup>2</sup> C–H), 2,893 (sp<sup>3</sup> C–H), 1,656 (C=O ester), 1,598 (C=C aromatic), 1,140 (C–O, ester).

### Synthesis of amide derivatives (4a–e) and (6a–e)

The hydroxy-substituted benzoic acids **3a–e** (0.01 mol), triethyl amine (0.01 mol), potassium iodide (0.01 mol) in dimethyl formamide (25 mL) and intermediate **2** (0.01 mol) were stirred overnight at room temperature (Scheme 1).



**Scheme 1** Synthesis of amide derivatives (4a–e).

**Abbreviation:** DMF, dimethylformamide.

After the completion of reaction, the mixture was poured into finely crushed ice by stirring and extracted with ethyl acetate (4×25 mL). The combined organic layer was washed with 5% HCl, 5% sodium hydroxide and finally with aqueous NaCl solution. The organic layer was dried over anhydrous magnesium sulfate, filtered and the solvent was removed under reduced pressure to afford the crude products **4a–e**. The title compounds **4a–e** were purified by silica gel column chromatography (n-hexane: ethyl acetate 3:1). The compounds **6a–e** were prepared by reacting intermediate **2** with substituted cinnamic acids **5a–e** (Scheme 2). The reaction conditions were same as described for the preparation of compounds **4a–e**.

### 2-[2-methyl-5-(propan-2-yl)anilino]-2-oxoethyl 3-hydroxybenzoate (**4a**)

Yield, 85%; melting point, 116°C–118°C;  $R_f=0.56$  (n-hexane:ethyl acetate 2:1); FTIR  $\nu_{\max}$   $\text{cm}^{-1}$ : 3,354 (N–H), 3,166 (O–H), 2,987 (sp<sup>2</sup> C–H), 2,913 (sp<sup>3</sup> C–H), 1,735 (C=O ester), 1,657 (C=O amide), 1,590 (C=C aromatic), 1,149 (C–O, ester); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>,  $\delta$  ppm): 8.63 (s, 1H, –NH), 7.76 (d,  $J=6.8$  Hz, 1H, H-6), 7.52 (s, 1H, H-2), 7.42 (dd,  $J=6.8, 7.6$  Hz, 1H, H-5), 7.36 (d,  $J=7.6$  Hz, 1H, H-4), 7.14 (d,  $J=2.4$  Hz, 1H, H-3'), 7.05 (d,  $J=7.6$  Hz, 1H, H-4'), 6.96 (s, 1H, H-6'), 4.98 (s, 2H, –CH<sub>2</sub>), 3.06 (sept, 1H,  $J=6.5$  Hz, H-1''), 2.32 (s, 3H, H-3''), 1.36 (s, 1H, –OH), 1.25 (d,  $J=6.5$  Hz, 6H, H-2''); <sup>13</sup>C NMR (CDCl<sub>3</sub>,  $\delta$  ppm): 165.6 (C=O ester), 162.5 (C=O, amide), 152.4 (C-3), 144.7 (C-1'), 138.6 (C-2'), 136.4 (C-5'), 133.6 (C-6), 131.3 (C-2), 129.6 (C-1), 127.6 (C-3'), 124.5 (C-4'), 122.3 (C-6'), 120.8 (C-4), 116.4 (C-5), 60.3 (–CH<sub>2</sub>), 27.4 (C-1''), 26.5 (C-3''), 20.3 (C-2'').

### 2-[2-methyl-5-(propan-2-yl)anilino]-2-oxoethyl 4-hydroxybenzoate (**4b**)

Yield, 80%; melting point, 121°C–123°C;  $R_f=0.53$  (n-hexane:ethyl acetate 2:1); FTIR  $\nu_{\max}$   $\text{cm}^{-1}$ : 3,332 (N–H), 3,153 (O–H), 2,966 (sp<sup>2</sup> C–H), 2,901 (sp<sup>3</sup> C–H),


1,732 (C=O ester), 1,645 (C=O amide), 1,593 (C=C aromatic), 1,148 (C–O, ester); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>,  $\delta$  ppm): 8.64 (s, 1H, –NH), 8.12 (dd,  $J=7.6, 2.4$  Hz, 2H, H-2, H-6), 7.34 (d,  $J=2.2$  Hz, 1H, H-2'), 7.19 (dd,  $J=7.6, 2.2$  Hz, 1H, H-4'), 7.04 (d,  $J=7.6$  Hz, 1H, H-6'), 6.92 (dd,  $J=7.6, 2.2$  Hz, 2H, H-3, H-5), 5.01 (s, 2H, –CH<sub>2</sub>), 4.93 (s, 1H, –OH), 2.72 (sept,  $J=6.4$  Hz, 1H, H-1''), 2.22 (s, 3H, –H-3''), 1.24 (d,  $J=6.4$  Hz, 6H, H-2''); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>,  $\delta$  ppm): 164.5 (C=O ester), 160.2 (C=O, amide), 154.5 (C-4), 149.7 (C-1'), 139.5 (C-2'), 136.5 (C-5'), 133.6 (C-3, C-5), 130.4 (C-1), 128.3 (C-3'), 126.4 (C-4'), 123.5 (C-6'), 119.4 (C-2, C-6), 61.4 (–CH<sub>2</sub>), 28.5 (C-1''), 26.8 (C-3''), 21.9 (C-2'').

### 2-[2-methyl-5-(propan-2-yl)anilino]-2-oxoethyl 2,4-dihydroxybenzoate (**4c**)

Yield, 78%; melting point, 136°C–138°C;  $R_f=0.44$  (n-hexane:ethyl acetate 2:1); FTIR  $\nu_{\max}$   $\text{cm}^{-1}$ : 3,364 (N–H), 3,163 (O–H), 2,966 (sp<sup>2</sup> C–H), 2,895 (sp<sup>3</sup> C–H), 1,728 (C=O ester), 1,651 (C=O amide), 1,590 (C=C aromatic), 1,160 (C–O, ester); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>,  $\delta$  ppm): 8.64 (s, 1H, –NH), 7.64 (d,  $J=7.4$  Hz, 1H, H-6), 7.19 (d,  $J=7.4$  Hz, 1H, H-5), 7.11 (d,  $J=2.2$  Hz, 1H, H-6'), 6.89 (s, 1H, H-3), 6.42 (d,  $J=7.6$  Hz, 1H, H-3'), 6.31 (dd,  $J=7.6, 2.2$  Hz, 1H, H-4'), 5.11 (s, 2H, –CH<sub>2</sub>), 4.67 (s, 2H, –OH), 2.850 (sept,  $J=7.1$  Hz, 1H, H-1''), 2.09 (s, 3H, H-3''), 1.13 (d,  $J=7.1$  Hz, 6H, H-2''); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>,  $\delta$  ppm): 166.5 (C=O ester), 162.1 (C=O amide), 160.3 (C-2), 155.6 (C-4), 148.2 (C-1'), 138.5 (C-2'), 136.3 (C-5'), 134.6 (C-6), 129.9 (C-4'), 127.7 (C-3'), 120.8 (C-6'), 112.3 (C-3), 108.3 (C-5), 105.1 (C-1), 59.3 (–CH<sub>2</sub>), 29.1 (C-1''), 27.5 (C-3''), 20.5 (C-2'').

### 2-[2-methyl-5-(propan-2-yl)anilino]-2-oxoethyl 3,4-dihydroxybenzoate (**4d**)

Yield, 76%; melting point, 126°C–128°C;  $R_f=0.48$  (n-hexane:ethyl acetate 2:1); FTIR  $\nu_{\max}$   $\text{cm}^{-1}$ : 3,376 (N–H), 3,171 (O–H), 2,973 (sp<sup>2</sup> C–H), 2,905 (sp<sup>3</sup> C–H), 1,730 (C=O ester), 1,671 (C=O amide), 1,592 (C=C aromatic), 1,156



**Scheme 2** Synthesis of amide derivatives (**6a–e**).

**Abbreviation:** DMF, dimethylformamide.

(C–O, ester);  $^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$  ppm): 8.45 (s, 1H, –NH), 7.69 (d,  $J=2.4$  Hz, 1H, H-2), 7.52 (dd,  $J=7.6, 2.4$  Hz, 1H, H-6), 7.36 (d,  $J=7.4$  Hz, 1H, H-5), 7.16 (d,  $J=1.4$  Hz, 1H, H-5'), 6.89 (d,  $J=7.6$  Hz, 1H, H-3'), 6.78 (dd,  $J=7.6, 1.4$  Hz, 1H, H-4'), 4.96 (s, 2H, –CH<sub>2</sub>), 4.40 (s, 2H, –OH), 2.80 (sept,  $J=5.8$  Hz, 1H, H-1''), 2.19 (s, 3H, H-3''), 1.19 (d,  $J=5.8$  Hz, 6H, H-2'');  $^{13}\text{C}$  NMR (DMSO- $d_6$ ,  $\delta$  ppm): 169.6 (C=O ester), 162.7 (C=O amide), 152.3 (C-3), 146.7 (C-4), 142.5 (C-1'), 138.5 (C-2'), 134.5 (C-5'), 131.9 (C-6), 128.6 (C-4'), 123.7 (C-3'), 122.5 (C-6'), 119.6 (C-2), 116.7 (C-5), 114.8 (C-1), 60.2 (–CH<sub>2</sub>), 29.5 (C-1''), 24.5 (C-3''), 22.3 (C-2'').

### 2-[2-methyl-5-(propan-2-yl)anilino]-2-oxoethyl 3,5-dihydroxybenzoate (4e)

Yield, 84%; melting point, 143°C–145°C;  $R_f=0.45$  (n-hexane:ethyl acetate 2:1); FTIR  $\nu_{\text{max}}$   $\text{cm}^{-1}$ : 3,385 (N–H), 3,154 (O–H), 2,954 (sp<sup>2</sup> C–H), 2,893 (sp<sup>3</sup> C–H), 1,731 (C=O ester), 1,643 (C=O amide), 1,590 (C=C aromatic), 1,160 (C–O, ester);  $^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$  ppm): 8.49 (s, 1H, –NH), 7.33 (d,  $J=7.4$  Hz, 1H, H-3'), 7.19 (d,  $J=7.4$  Hz, 1H, H-4'), 6.98 (d,  $J=1.8$  Hz, 2H, H-3, H-5), 6.87 (d,  $J=1.8$  Hz, 1H, H-4), 6.67 (s, 1H, H-6'), 5.02 (s, 2H, –CH<sub>2</sub>), 4.62 (s, 2H, –OH), 2.83 (sept,  $J=6.2$  Hz, 1H, H-1''), 2.20 (s, 3H, H-3''), 1.12 (d,  $J=6.2$  Hz, 6H, H-2'');  $^{13}\text{C}$  NMR (DMSO- $d_6$ ,  $\delta$  ppm): 169.1 (C=O ester), 161.2 (C=O amide), 158.3 (C-3, C-5), 155.3 (C-1'), 149.0 (C-2'), 139.1 (C-5'), 133.9 (C-2, C-6), 130.1 (C-4'), 126.3 (C-3'), 123.1 (C-6'), 109.3 (C-4), 108.4 (C-1), 62.7 (–CH<sub>2</sub>), 25.5 (C-1''), 22.6 (C-3''), 19.6 (C-2'').

### 2-[2-methyl-5-(propan-2-yl)anilino]-2-oxoethyl (2E)-3-phenylprop-2-enoate (6a)

Yield, 86%; melting point, 138°C–140°C;  $R_f=0.62$  (n-hexane:ethyl acetate 2:1); FTIR  $\nu_{\text{max}}$   $\text{cm}^{-1}$ : 3,381 (N–H), 2,951 (sp<sup>2</sup> C–H), 2,898 (sp<sup>3</sup> C–H), 1,729 (C=O ester), 1,665 (C=O amide), 1,597 (C=C aromatic), 1,148 (C–O, ester);  $^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$  ppm): 8.21 (s, 1H, –NH), 7.62 (d,  $J=16.0$  Hz, 1H, H-2), 7.48 (dd,  $J=7.2, 2.4$  Hz, 2H, H-2', H-6'), 7.35–7.39 (m, 3H, H-3', H-4', H-5'), 7.15 (d,  $J=7.2$  Hz, 1H, H-3''), 7.01 (d,  $J=7.2$  Hz, 1H, H-4''), 6.91 (s, 1H, H-6''), 6.61 (d,  $J=16.0$  Hz, 1H, H-1), 4.97 (s, 2H, –CH<sub>2</sub>), 2.81 (sept,  $J=6.8$  Hz, 1H, H-1'''), 2.28 (s, 3H, H-3'''), 1.21 (d,  $J=6.8$  Hz, 6H, H-2''');  $^{13}\text{C}$  NMR (DMSO- $d_6$ ,  $\delta$  ppm): 166.8 (C=O ester), 160.5 (C=O, amide), 151.3 (C-1'), 140.9 (C-2), 137.2 (C-2''), 135.3 (C-5''), 130.3 (C-2', C-6'), 128.4 (C-3', C-5'), 124.8 (C-4'), 123.5 (C-1'), 121.2 (C-3''), 119.2 (C-4''), 115.2 (C-6''), 60.5 (–CH<sub>2</sub>), 27.8 (C-1'''), 24.6 (C-3'''), 19.5 (C-2''').

### 2-[2-methyl-5-(propan-2-yl)anilino]-2-oxoethyl (2E)-3-(2-hydroxyphenyl)prop-2-enoate (6b)

Yield, 82%; melting point, 190°C–192°C;  $R_f=0.54$  (n-hexane:ethyl acetate 2:1); FTIR  $\nu_{\text{max}}$   $\text{cm}^{-1}$ : 3,365 (N–H), 3,138 (O–H), 2,965 (sp<sup>2</sup> C–H), 2,895 (sp<sup>3</sup> C–H), 1,738 (C=O ester), 1,673 (C=O amide), 1,595 (C=C aromatic), 1,162 (C–O, ester);  $^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$  ppm): 8.24 (s, 1H, –NH), 7.83 (d,  $J=16.0$  Hz, 1H, H-2), 7.62 (d,  $J=7.6$  Hz, 2H, H-6'), 7.58 (dd,  $J=7.6, 2.2$  Hz, 1H, H-4'), 7.42 (dd,  $J=7.6, 2.4$  Hz, 2H, H-5'), 7.38 (d,  $J=7.6$  Hz, 1H, H-3'), 7.18 (d,  $J=7.4$  Hz, 1H, H-3''), 7.09 (d,  $J=7.4$  Hz, 1H, H-4''), 6.91 (s, 1H, H-6''), 6.56 (d,  $J=16.0$  Hz, 1H, H-1), 5.02 (s, 2H, –CH<sub>2</sub>), 3.13 (sept,  $J=7.1$  Hz, 1H, H-1'''), 2.31 (s, 3H, H-3'''), 1.21 (d,  $J=7.1$  Hz, 6H, H-2''');  $^{13}\text{C}$  NMR (DMSO- $d_6$ ,  $\delta$  ppm): 165.9 (C=O ester), 162.2 (C=O, amide), 156.8 (C-1'), 147.2 (C-2), 141.3 (C-2''), 138.9 (C-5''), 129.4 (C-3', C-5'), 127.3 (C-4'), 125.2 (C-1'), 121.5 (C-3''), 119.4 (C-4''), 114.3 (C-2', C-6'), 111.1 (C-6''), 62.4 (–CH<sub>2</sub>), 28.4 (C-1'''), 25.4 (C-3'''), 21.8 (C-2''').

### 2-[2-methyl-5-(propan-2-yl)anilino]-2-oxoethyl (2E)-3-(4-hydroxyphenyl)prop-2-enoate (6c)

Yield, 84%; melting point, 206°C–208°C;  $R_f=0.52$  (n-hexane:ethyl acetate 2:1); FTIR  $\nu_{\text{max}}$   $\text{cm}^{-1}$ : 3,363 (N–H), 3,193 (O–H), 2,975 (sp<sup>2</sup> C–H), 2,898 (sp<sup>3</sup> C–H), 1,725 (C=O ester), 1,652 (C=O amide), 1,596 (C=C aromatic), 1,166 (C–O, ester);  $^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$  ppm): 8.78 (s, 1H, –NH), 7.62 (d,  $J=16.0$  Hz, 1H, H-2), 7.53 (dd,  $J=7.4, 2.2$  Hz, 2H, H-2', H-6'), 7.39 (dd,  $J=7.4, 2.2$  Hz, 2H, H-3', 5'), 7.19 (d,  $J=7.6$  Hz, 1H, H-3''), 7.08 (d,  $J=7.6$  Hz, 1H, H-4''), 6.98 (s, 1H, H-6''), 6.68 (d,  $J=16.0$  Hz, 1H, H-1), 4.99 (s, 2H, –CH<sub>2</sub>), 2.98 (sept,  $J=6.2$  Hz, 1H, H-1'''), 2.31 (s, 3H, H-3'''), 1.21 (d,  $J=6.2$  Hz, 6H, H-2''');  $^{13}\text{C}$  NMR (DMSO- $d_6$ ,  $\delta$  ppm): 166.3 (C=O ester), 161.3 (C=O, amide), 156.5 (C-1'), 142.8 (C-2), 139.5 (C-2''), 136.4 (C-5''), 132.5 (C-3', C-5'), 130.4 (C-4'), 127.3 (C-1'), 121.6 (C-3''), 119.4 (C-4''), 117.5 (C-2', C-6'), 112.7 (C-6''), 62.4 (–CH<sub>2</sub>), 28.4 (C-1'''), 25.5 (C-3'''), 21.4 (C-2''').

### 2-[2-methyl-5-(propan-2-yl)anilino]-2-oxoethyl (2E)-3-(2,4-dihydroxyphenyl)prop-2-enoate (6d)

Yield, 76%; melting point, 224°C–226°C;  $R_f=0.44$  (n-hexane:ethyl acetate 2:1); FTIR  $\nu_{\text{max}}$   $\text{cm}^{-1}$ : 3,387 (N–H), 3,158 (O–H), 2,958 (sp<sup>2</sup> C–H), 2,890 (sp<sup>3</sup> C–H), 1,735 (C=O ester),



1,648 (C=O amide), 1,598 (C=C aromatic), 1,168 (C–O, ester); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, δ ppm): 8.89 (s, 1H, –NH), 7.78 (d, *J*=16.0 Hz, 1H, H-2), 7.49 (d, *J*=7.2 Hz, 1H, H-6'), 7.43 (d, *J*=7.2 Hz, 1H, H-5'), 7.39 (s, 1H, H-3'), 7.19 (d, *J*=7.2 Hz, 1H, H-3''), 7.02 (d, *J*=6.6 Hz, 1H, H-4''), 6.94 (s, 1H, H-6''), 6.62 (d, *J*=16.0 Hz, 1H, H-1), 5.01 (s, 2H, –CH<sub>2</sub>), 3.21 (sept, *J*=6.8 Hz, 1H, H-1'''), 2.35 (s, 3H, H-3'''), 1.31 (d, *J*=7.2 Hz, 6H, H-2'''); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, δ ppm): 166.3 (C=O ester), 160.2 (C=O, amide), 157.6 (C-1''), 147.9 (C-2), 146.2 (C-2''), 137.5 (C-5''), 130.5 (C-3'), 127.1 (C-5'), 126.4 (C-4'), 127.2 (C-1'), 125.5 (C-3''), 123.2 (C-4''), 121.6 (C-2'), 118.5 (C-6'), 112.7 (C-6''), 62.4 (–CH<sub>2</sub>), 27.3 (C-1'''), 26.3 (C-3'''), 21.3 (C-2''').

## 2-[2-methyl-5-(propan-2-yl)anilino]-2-oxoethyl (2E)-3-(4-chlorophenyl)prop-2-enoate (6e)

Yield, 86%; melting point, 139°C–141°C; *R*<sub>f</sub>=0.62 (n-hexane:ethyl acetate 2:1); FTIR *v*<sub>max</sub> cm<sup>-1</sup>: 3,365 (N–H), 2,967 (sp<sup>2</sup> C–H), 2,898 (sp<sup>3</sup> C–H), 1,735 (C=O ester), 1,656 (C=O amide), 1,598 (C=C aromatic), 1,148 (C–O, ester); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, δ ppm): 8.24 (s, 1H, –NH), 7.82 (d, *J*=16.0 Hz, 1H, H-2), 7.51 (d, *J*=7.6 Hz, 2H, H-2', 6'), 7.36 (d, *J*=7.6 Hz, 1H, H-3''), 7.16 (d, *J*=7.6 Hz, 1H, H-4''), 6.98 (s, 1H, H-6''), 6.77 (d, *J*=7.6 Hz, 2H, H-3', H-5'), 6.48 (d, *J*=16.0 Hz, 1H, H-1), 5.01 (s, 2H, –CH<sub>2</sub>), 3.11 (sept, *J*=5.8 Hz, 1H, H-1'''), 2.48 (s, 3H, H-3'''), 1.19 (d, *J*=5.8 Hz, 6H, H-2'''); <sup>13</sup>C NMR (CDCl<sub>3</sub>, δ ppm): 167.6 (C=O ester), 161.3 (C=O, amide), 153.4 (C-1''), 148.8 (C-2), 137.6 (C-2''), 134.6 (C-5''), 131.8 (C-2', C-6'), 129.5 (C-3', C-5'), 127.9 (C-4'), 124.5 (C-1'), 122.5 (C-3''), 120.4 (C-4''), 118.3 (C-6''), 62.9 (–CH<sub>2</sub>), 29.4 (C-1'''), 25.6 (C-3'''), 22.3 (C-2''').

## Mushroom tyrosinase inhibition assay

Mushroom tyrosinase (Sigma-Aldrich, St Louis, MO, USA) inhibition was performed following our previously reported methods.<sup>25</sup> In detail, 140 μL of phosphate buffer (20 mM, pH 6.8), 20 μL of mushroom tyrosinase (30 U/mL) and 20 μL of the inhibitor solution were placed in the wells of a 96-well microplate. After preincubation for 10 min at room temperature, 20 μL of L-DOPA (3,4-dihydroxyphenylalanine, Sigma-Aldrich) (0.85 mM) was added and the assay plate was further incubated at 25°C for 20 min. Afterwards, the absorbance of dopachrome was measured at 475 nm using a microplate reader (Optimax Max Tunable, Sunnyvale, CA, USA). Kojic acid was used as a reference inhibitor and phosphate buffer was used as a negative control. The extent of inhibition by the test compounds was expressed as the

percentage of concentration necessary to achieve 50% inhibition (IC<sub>50</sub>). Each concentration was analyzed in three independent experiments. IC<sub>50</sub> values were determined by data analysis and by a graphing software, Origin 8.6, 64-bit.

Percent inhibition of tyrosinase was calculated using the following equation:

$$\text{Inhibition (\%)} = \left[ \frac{B - S}{B} \right] \times 100$$

Here, B and S are the absorbance of the blank and samples.

## Elastase inhibition assay

Elastase (elastase from porcine pancreas) inhibition assay was performed based on the methods reported by Kraunsoe et al<sup>26</sup> and Kim et al<sup>27</sup> with a few modifications. In order to perform elastase inhibition assay, the amount of released *p*-nitroaniline, which was hydrolyzed from the substrate (N-succinyl-Ala-Ala-Ala-*p*-nitroanilide) by elastase, was determined by measuring the absorbance at 410 nm. In detail, 0.8 mM solution of N-succinyl-Ala-Ala-Ala-*p*-nitroanilide was prepared in a 0.2 M Tris–HCl buffer (pH 8.0) and this buffer (130 μL) was added to the test sample (10 μL) in a 96-well microplate. The microplate was pre-incubated for 10 min at 25°C before elastase (0.0375 unit/mL) stock solution (10 μL) was added. After the addition of the enzyme, the microplate was kept at 25°C for 30 min and the absorbance was measured at 410 nm using microplate reader. All experiments were carried out in triplicate and elastase inhibitory activity was calculated according to the following formula:

$$\text{Elastase inhibition activity (\%)} = \frac{\text{OD}_{\text{control}} - \text{OD}_{\text{sample}}}{\text{OD}_{\text{control}}} \times 100$$

where OD<sub>control</sub> is the optical density of the control and OD<sub>sample</sub> is the optical density of the sample. Oleanolic acid was used as the standard inhibitor for elastase.

## Free radical scavenging assay

Free radical scavenging activity of amide derivatives was determined based on previously reported methods with few modifications.<sup>28,29</sup> The assay solution consisted of 100 μL of DPPH (150 μM) and 20 μL of increasing concentration of test compounds, and the volume was adjusted to 200 μL in each well with DMSO. The reaction mixture was then incubated

for 30 min at room temperature. Ascorbic acid (vitamin C) was used as a reference inhibitor. The assay measurements were carried out using a microplate reader (OPTI<sub>Max</sub>, Tunable) at 517 nm. The reaction rates were compared and the percent inhibition caused by the presence of tested inhibitors was calculated. Each concentration was analyzed in three independent experiments run in triplicate.

## Kinetic analysis of the inhibition of tyrosinase

A series of experiments was performed to calculate the inhibitory kinetics of compounds **4c**, **6a**, **6b** and **6d** following the previously reported method.<sup>30</sup> The compounds' concentrations were as follows: 0, 3.125, 6.25 and 12.5  $\mu\text{M}$  for **4c**; 0, 0.3915 and 0.783  $\mu\text{M}$  for **6a**; 0, 0.453, 0.965, 1.813 and 3.626  $\mu\text{M}$  for **6b**; and 0, 0.08, 0.16 and 0.32  $\mu\text{M}$  for **6d**. Substrate L-DOPA concentration was between 0.0625 and 2 mM in all kinetic studies. Preincubation and measurement time was the same as discussed in mushroom tyrosinase inhibition assay protocol. Maximal initial velocity was determined from initial linear portion of absorbance up to 5 min after addition of enzyme at a 30 s interval. The type of inhibition was determined by using Lineweaver–Burk plots. The enzyme inhibitor (EI) dissociation constant  $K_i$  was determined by secondary plot of  $1/V$  versus inhibitor concentrations, while enzyme–substrate–inhibitor (ESI)-dissociation constant  $K_i'$  was determined by intercept versus inhibitor concentrations. The reversible kinetics of the EI complex was also determined for different concentrations of compound **6d** versus the enzyme concentration (4, 6, 8, 10, 15 and 20  $\mu\text{g/mL}$ ).

## Human tyrosinase inhibition assay

### Cell culture and preparation of tyrosinase

A375 human melanoma cells were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA). A375 cells were grown in Dulbecco's Modified Eagle's Medium (Invitrogen, Burlington, ON, Canada) supplemented with L-glutamine, 10% (v/v) fetal bovine serum (Invitrogen), 50  $\mu\text{g/mL}$  streptomycin (Sigma-Aldrich), 50 units/mL penicillin (Sigma-Aldrich) and supplemented with 200  $\mu\text{M}$  of L-tyrosine for tyrosinase induction. Cell cultures were incubated at 37°C, in a humidified atmosphere of 5%  $\text{CO}_2$ . Cells were scraped out from the tissue culture plate with phosphate-buffered saline (PBS) and were homogenized at 4°C in PBS. The homogenate was centrifuged at 1,000 $\times g$  for 10 min. The precipitate was sonicated in PBS on ice and the mixture was centrifuged at 10,000 $\times g$  for 30 min.

The supernatant containing tyrosinase was used for the measurement of the inhibitory effects.

### Tyrosinase inhibition assay

The tyrosinase inhibitory activity of the synthesized amides was determined following the previously reported method with few modifications.<sup>31,32</sup> The assay reaction mixture (200  $\mu\text{L}$ ) contained 3.3 mM L-DOPA in 0.33 M phosphate buffer (pH 7.0) and the enzyme in the presence and absence of inhibitors. Fifteen or 20 units of tyrosinase was used to determine the % inhibition. The reaction mixture was incubated at 37°C for 10 min and the absorbance was recorded at 475 nm using a microplate reader (OPTI Max, Tunable). One unit of enzyme was defined as the amount of enzyme that increases the absorbance value by 0.001 at 475 nm per minute under the same conditions as described earlier.

### In vivo depigmentation assay in zebrafish

In vivo depigmentation assay was performed in zebrafish according to the previously described method.<sup>33</sup>

### Zebrafish husbandry

Adult wild-type zebrafish (*Danio rerio*) were purchased from a commercial dealer and were acclimated for 1 month in standard laboratory conditions using a photoperiod of 14 h light and 10 h dark at a temperature of 28.5°C. Fish were fed two times daily with dry food and live brine shrimp larvae. They were kept in thermostatic tanks under constant chemical, biological and mechanical water filtration and aeration. Embryos were obtained from natural spawning that was induced at the morning by turning on the light. Collection of embryos was completed within 30 min. All procedures were performed as described in the "Principles of Laboratory Animal Care" (NIH publication no 85-23, revised 1985), and the study was approved by the Institutional Review Board of Kongju National University (IRB No 2011-2).

### Compound treatment and phenotype-based evaluation

The collected synchronized embryos were arrayed by pipette into a 96-well plate: two to three embryos per well with 200  $\mu\text{L}$  of E3 medium (NaCl 5 mM, KCl 0.17 mM,  $\text{CaCl}_2$  0.33 mM and  $\text{MgSO}_4$  0.33 mM). The most potent compound **6d** solution (in 0.1% DMSO) was added to the E3 medium from 9 to 72 hpf (hours post-fertilization, a total exposure time of 63 h). The positive control was treated with kojic acid. Dechorionated embryos were anesthetized in tricaine methanesulfonate MS-222 solution (Sigma-Aldrich),

mounted in 1% methyl cellulose on a depression slide and photographs were taken using stereomicroscope (SMZ745T; Nikon, Shinagawa, Japan) for observation. Pixel measurements were carried out using ImageJ software package (National Institutes of Health, Bethesda, MD, USA).

## Determination of melanin contents in zebrafish

Melanin contents in zebrafish were determined following the previously reported method.<sup>34,35</sup> For melanin contents determination, 50  $\mu$ M dose was selected on the basis of in vivo depigmentation results. The collected synchronized embryos were arrayed by dropper into the dish: 20 $\pm$ 2 embryos were used in the dish and treated with compound **6d** and 50  $\mu$ M of reference drug kojic acid in 3 mL of E3 medium. After 72 hpf, embryos were anesthetized in tricaine methanesulfonate MS-222 solution. After anesthetizing, embryos were washed three times with E3 medium and eyes were removed from all the treated and non-treated embryos. Embryos extract (pellet) was prepared by homogenization and centrifugation, and the pellet was dissolved in 1 mL of 1N NaOH at 100°C for 10 min. The level of melanin was measured at an absorbance of 405 nm, and the result was compared with a standard curve of synthetic melanin. All experiments were repeated three times.

## Zebrafish toxicity assay

Zebrafish toxicity assay was performed according to the previously reported method.<sup>36</sup> Prior to compounds treatment, 48 hpf embryos were enzymatically dechorionated using pronase (protease from *Streptomyces griseus*, 3 mg/mL; Sigma-Aldrich) for 15 min, then rinsed with E3 medium three times and two to three embryos were dispensed in 96-well plate with 200  $\mu$ L of E3 medium. Embryos were treated with 10, 20 and 50  $\mu$ M doses of compounds and pates were maintained at 28°C for further 72 h. The survival rate of larvae was assessed at day 5, and during the experiment no food was provided to larvae. In order to evaluate any extent of apoptotic cellular death, after 3 days of treatment (total 5 days), embryos were stained with 1  $\mu$ g/mL of acridine orange in E3 medium for 30 min. Excess dye was removed by washing three times with E3 medium. The embryos were anesthetized and photographs were taken as described in section “In vivo depigmentation zebrafish assay”.

## Computational studies

### Retrieval of protein structure

The three dimensional (3D) crystal structure of mushroom tyrosinase (*Agaricus bisporus*) (PDBID: 2Y9X) was retrieved

from Protein Data Bank (PDB) (<http://www.rcsb.org>). The energy minimization of target protein was carried out by employing conjugate gradient algorithm and Amber force field in UCSF Chimera 1.10.1.<sup>37</sup> Stereochemical properties and Ramachandran graph and values<sup>38</sup> of mushroom tyrosinase were assessed by Molprobit server,<sup>39</sup> while the hydrophobicity graph was generated by Discovery Studio 4.1 Client.<sup>40</sup> The protein architecture and statistical percentage values of helices, beta-sheets, coils and turns were accessed by VADAR 1.8.<sup>41</sup>

### Candidate structures

The synthesized amide derivatives **4a–e** and **6a–e** were drawn by ACD/ChemSketch tool. The designed ligands were further visualized and minimized by UCSF Chimera 1.10.1. The biochemical properties of these compounds **4a–e** and **6a–e** were predicted by various computational tools such as Molinspiration (<http://www.molinspiration.com/>) and Molsoft (<http://www.molsoft.com/>). Lipinski's rule of five (RO5) was justified by Molsoft and Molinspiration tools.

### Molecular docking

Molecular docking experiment was employed on all synthesized ligands **4a–e** and **6a–e** against mushroom tyrosinase using diverse PyRx tool.<sup>42</sup> The preferred orientation of ligands within the active region of target proteins was determined in docking studies. To run the docking experiment, grid box parametric dimension values were adjusted as X =61.0781, Y =56.3001 and Z =63.1015, whereas the centered values were fixed as X =-2.9272, Y =22.0164 and Z =-32.4883, respectively. The default exhaustiveness value was set as 8 to obtain the finest binding conformational pose of protein-ligand docked complexes. All compounds were docked separately against the crystal structure of mushroom tyrosinase. The docked complexes were further evaluated on lowest binding energy (Kcal/mol) values and hydrogen and hydrophobic bond analysis using Discovery Studio (4.1) and UCSF Chimera 1.10.1. 2D graphical depictions of all other compounds were carried out by LIGPLOT.<sup>43</sup>

### Molecular dynamics (MD) simulations

Based on in vitro analysis, docking energies and conformational pose analysis, four best complexes were selected for MD simulation. Groningen Machine for Chemicals Simulations (GROMACS) 4.5.4 package<sup>44</sup> with GROMOS 53A6 force field was applied on all complexes to interpret the backbone residual flexibility.<sup>45</sup> The receptor and ligands topology files were created using GROMOS 53A6 force

field and online PRODRG Server,<sup>46</sup> respectively. Moreover, the receptor–ligand complexes were solvated and placed in a cubic box center adjusted at a distance of 9 Å. Ions were added to neutralize the charge of the system. Energy minimization (nsteps = 50,000) was done by steepest descent method (1,000 ps). Energy calculation was done by Particle Mesh Ewald method,<sup>47</sup> whereas covalent bond constraints were calculated by linear constraint solver algorithm.<sup>48</sup> For final MD setup in md.mdp file, time step for integration was adjusted as 0.002 ps, while the cut-off distance for short range neighbor list was adjusted as 0.8 nm. The MD run was set to 15,000 ps with nsteps = 750,000 for each protein–ligand complexes, and trajectories files analysis was done by Xmgrace tool (<http://plasma-gate.weizmann.ac.il/Grace/>).

## Results and discussion

### Chemistry

The title amide analogues **4a–e** and **6a–e** were prepared following the previously described method<sup>49</sup> with slight modification shown in Schemes 1 and 2. The 2-amino-*p*-cymene in the first step is converted into 2-chloro-N-[2-methyl-5-(propan-2-yl)phenyl]acetamide (**2**) by treating with chloroacetyl chloride in the presence of (C<sub>2</sub>H<sub>5</sub>)<sub>3</sub>N and anhydrous methylene chloride. The structure of the intermediate **2** was ascertained by the presence of amide carbonyl (–NHC=O) stretching at 1,656 cm<sup>-1</sup> and –NH stretching at 3,354 cm<sup>-1</sup> in FTIR spectra. The compounds **4a–e** and **6a–e** were synthesized by simple nucleophilic replacement of chloro group from intermediate **2** by carboxylic group (–COOH) of substituted benzoic acids **3a–e** and cinnamic acids **5a–e**, respectively. The structures of the final products were confirmed by FTIR, <sup>1</sup>HNMR and <sup>13</sup>CNMR spectral data.

### In vitro enzymes inhibition assay

Mushroom tyrosinase and elastase inhibitory activities were determined and it was found that most of the synthesized amides showed better tyrosinase inhibition than standard drug. The hydroxylated amides with cinnamic acid moiety showed higher tyrosinase inhibitory activity than those with benzoic acid residue. The IC<sub>50</sub> value of compound **6d** bearing 2,4-dihydroxy substituted cinnamic acid functionality was 0.15 μM, which explains its excellent tyrosinase inhibitory activity, whereas the IC<sub>50</sub> value of standard kojic acid was 17.20 μM. The same compound (**6d**) also displayed higher elastase inhibitory potential compared to all other synthesized amide derivatives (Table 1). Bioassay results showed that the

**Table 1** Inhibitory effects of amide derivatives **4a–e** and **6a–e** on mushroom tyrosinase and porcine pancreas elastase

Compounds	Tyrosinase activity IC <sub>50</sub> ± SEM (μM)	Elastase activity IC <sub>50</sub> ± SEM (μM)
<b>4a</b>	10.97±1.3	41.88±7.5
<b>4b</b>	17.98±2.5	81.85±15.2
<b>4c</b>	1.80±0.31	32.93±9.4
<b>4d</b>	10.96±1.8	24.31±5.7
<b>4e</b>	20.20±4.9	33.73±7.2
<b>6a</b>	0.78±0.09	5.01±1.8
<b>6b</b>	1.81±0.4	13.32±3.2
<b>6c</b>	1.41±0.1	23.32±4.2
<b>6d</b>	0.15±0.01	3.73±0.5
<b>6e</b>	16.71±3.1	35.80±8.2
Kojic acid	17.20±2.6	–
Oleanolic acid	–	1.69±0.05

**Note:** Values are expressed as IC<sub>50</sub> ± SEM.

**Abbreviation:** SEM, standard error of mean.

substitution of hydroxyl groups at phenyl ring is the decisive factor of inhibitory activity.


In vitro human tyrosinase inhibition assays showed that compound **6d** exhibited 91.9% inhibitory capacity at 50 μg/mL (Table 2). This shows that the amide **6d** has a greater potential to inhibit human tyrosinase compared to standard kojic acid (72.9% inhibitory capacity). Hence, we propose that substitution of hydroxyl group in phenyl ring in case of compound **6d** impedes the molecule to interact well with the active sites of enzyme. The kinetic analysis and docking studies helped us to explore the mode of binding and residual interactions between the enzyme and synthesized inhibitors.

**Table 2** Inhibitory effects of amide derivatives **4a–e** and **6a–e** on human tyrosinase (from melanoma cells) free radical scavenging

Compounds	Human tyrosinase % inhibition	Free radical scavenging % inhibition
<b>4a</b>	61.25±3.9	25.23±1.0
<b>4b</b>	53.83±5.3	1.70±0.5
<b>4c</b>	66.67±6.4	2.4±0.6
<b>4d</b>	56.85±6.5	91.78±2.0
<b>4e</b>	54.62±5.8	7.12±0.8
<b>6a</b>	82.35±8.5	1.39±0.5
<b>6b</b>	53.70±4.2	1.15±0.4
<b>6c</b>	55.83±5.7	8.51±1.0
<b>6d</b>	91.87±8.43	23.51±2.0
<b>6e</b>	57.40±4.92	7.50±1.0
Kojic acid	72.94±5.92	–
Oleanolic acid	–	95.60±1.0

**Notes:** For human tyrosinase, the concentration of all inhibitors and kojic acid was 50 μg/mL, and for free radical scavenging, the concentration of all inhibitors and vitamin C was 100 μg/mL. Values are expressed as mean ± standard error of mean.






**Figure 1** Lineweaver–Burk plots for inhibition of tyrosinase in the presence of amide **4c**.

**Notes:** (A) Concentrations of **4c** were 0, 3.125, 6.25 and 12.5  $\mu\text{M}$  and that of substrate L-DOPA were 0.125, 0.25, 0.5, 1 and 2 mM. (B) The plot of the slope. The lines were drawn using linear least squares fit.

## Kinetic mechanism


Among the synthesized amide derivatives, **4c**, **6a**, **6b** and **6d** were selected to determine their inhibition type and inhibition constants on mushroom tyrosinase. The potential of these derivatives to inhibit the free enzyme and enzyme–substrate complex was determined in terms of EI and ESI constants, respectively. The kinetic studies of the enzyme

by Lineweaver–Burk plot of  $1/V$  versus  $1/[L-DOPA]$  in the presence of different inhibitors concentrations gave a series of straight lines as shown in Figures 1–4A. Figures 2A and 3A show that compounds **6a** and **6b** intersected within the second quadrant. The analysis showed that  $V_{\text{max}}$  decreased with increasing  $K_m$  in the presence of increasing concentrations of compounds **6a** and **6b**, respectively. This behavior




**Figure 2** Lineweaver–Burk plots for inhibition of tyrosinase in the presence of amide **6a**.

**Notes:** (A) Concentrations of **6a** were 0, 0.3915, and 0.783  $\mu\text{M}$  and those of substrate L-DOPA were 0.125, 0.25, 0.5, 1 and 2 mM. (B) The plot of the slope and (C) of the vertical intercepts versus inhibitor **6a** concentrations to determine inhibition constants. The lines were drawn using linear least squares fit.



**Figure 3** Lineweaver–Burk plots for inhibition of tyrosinase in the presence of amide **6b**. **Notes:** (A) Concentrations of **6b** were 0, 0.453, 0.965, 1.813 and 3.626 μM and those of substrate L-DOPA were 0.125, 0.25, 0.5, 1 and 2 mM. (B) The plot of the slope and (C) of the vertical intercepts versus inhibitor **6b** concentrations to determine inhibition constants. The lines were drawn using linear least squares fit.



**Figure 4** Lineweaver–Burk plots for inhibition of tyrosinase in the presence of amide **6d**. **Notes:** (A) Concentrations of **6d** were 0, 0.08, 0.16 and 0.32 μM and those of substrate L-DOPA concentrations were 0.125, 0.25, 0.5, 1 and 2 mM. (B) The plot of the slope. The lines were drawn using linear least squares fit.

**Table 3** Kinetic parameters of mushroom tyrosinase for L-DOPA activity in the presence of different concentration of compounds **4c**, **6a**, **6b** and **6d**

Code	Dose ( $\mu\text{M}$ )	$V_{\text{max}}$ ( $\Delta\text{A}/\text{sec}$ )	$K_m$ (mM)	Inhibition type	Inhibition	$K_i$ ( $\mu\text{M}$ )	$K_i'$ ( $\mu\text{M}$ )
<b>4c</b>	0.0	$5.090 \times 10^{-6}$	0.138	Non-competitive	–	0.188	–
	3.125	$2.545 \times 10^{-6}$	0.138				
	6.25	$1.696 \times 10^{-6}$	0.138				
	12.5	$1.288 \times 10^{-6}$	0.138				
<b>6a</b>	0.0	$5.621 \times 10^{-6}$	0.112	Mixed inhibition	–	0.84	1.4
	0.3915	$4.294 \times 10^{-6}$	0.126				
	0.783	$3.909 \times 10^{-6}$	0.136				
<b>6b</b>	0.0	$5.555 \times 10^{-7}$	0.089	Mixed inhibition	–	2.2	3.8
	0.453	$4.819 \times 10^{-7}$	0.108				
	0.965	$3.947 \times 10^{-7}$	0.119				
	1.813	$3.067 \times 10^{-7}$	0.123				
	3.626	$2.592 \times 10^{-7}$	0.131				
<b>6d</b>	0.0	$1.161 \times 10^{-5}$	0.217	Non-competitive	Irreversible	0.217	–
	0.08	$9.598 \times 10^{-6}$	0.217				
	0.16	$6.233 \times 10^{-6}$	0.217				
	0.32	$4.787 \times 10^{-6}$	0.217				


of compounds **6a** and **6b** indicated that it inhibits tyrosinase by two different pathways: competitively forming EI complex and non-competitively interrupting ESI complex. The EI dissociation constants  $K_i$  (Figures 2B and 4B) of compounds **6a** and **6b** are shown by the secondary plots of slope versus concentration of compounds, whereas the ESI dissociation constants  $K_i'$  are shown by the secondary plots of intercept versus concentration of compounds (Figures 2C and 3C). A lower value of  $K_i$  than  $K_i'$  pointed out stronger binding between enzyme and compounds **6a** and **6b**, which suggested preferred competitive over non-competitive manners (Table 3).


In case of compounds **4c** and **6d**, Lineweaver-Burk plot gave a family of straight lines, all of which intersected at the same point on the x-axis (Figures 1A and 4A). The analysis showed that  $1/V_{\text{max}}$  increased to a new value but  $K_m$  remained the same as a result of increase in the concentrations of compounds **4c** and **6d**. This behavior indicates that compounds **4c** and **6d** inhibit tyrosinase non-competitively to form EI complex. Secondary plot of slope against concentration of **4c** and **6d** shows the EI dissociation constant ( $K_i$ ) (Figures 1B and 4B). The inhibitory mechanism of mushroom tyrosinase by compounds **6d** at different concentrations (0.0, 0.08, 0.16 and 0.32  $\mu\text{M}$ ) was investigated. The plots of the remaining enzyme activity versus the concentration of enzyme (4, 6, 8, 10, 15 and 20  $\mu\text{g}/\text{mL}$ ) at different inhibitor concentrations for the catalysis of L-DOPA gave a series of parallel straight lines with the same slopes indicating that the inhibitory

effect of **6d** on tyrosinase was irreversible (Figure 5). These results suggest that the compound **6d** effectively inhibited the enzyme by binding to its binuclear active site irreversibly.<sup>50</sup>

### In vivo depigmentation assay in zebrafish

Zebrafish is a very important vertebrate animal model because it possesses similar gene sequence system to human.<sup>51</sup> Zebrafish embryos were used to determine the depigmentation activity of compound **6d** through in vivo assay. The inhibitory

**Figure 5** Effect of various doses of mushroom tyrosinase on its activity for the catalysis of L-DOPA against different concentration of inhibitor **6d**.



**Figure 6** Effect of inhibitor **6d** on pigmentation of zebrafish.

**Notes:** Embryos were treated with 5, 10, 20 and 50 μM of **6d** and positive control kojic acid. (A) Representation of the pigmentation levels of zebrafish treated with inhibitor **6d** and kojic acid. (B) Pixels comparison of the depigmenting potency of **6d** and kojic acid. \* $P < 0.05$ ; \*\* $P < 0.01$ .

effects of **6d** on the pigmentation of zebrafish were evaluated by adding **6d** at concentrations of 5, 10, 20 and 50 μM to the embryos, and same concentrations were used for positive control kojic acid. Compound **6d** significantly decreased ( $P < 0.05$ , Figure 6) the pigmentation level to about 57.3%, while positive control kojic acid decreased the pigmentation level to 24.2% at 50 μM. Moreover, inhibitor **6d** showed better depigmenting effects than kojic acid at 10 and 20 μM.


## Determination of melanin contents in zebrafish

Melanin contents were measured using the extract of zebrafish embryos. Results showed that melanin contents significantly ( $P < 0.001$ ) decreased in the **6d**-treated zebrafish embryos at 50 μM compared to non-treated embryos and reference drug. Kojic acid only slightly reduced the melanin contents in zebrafish embryos, whereas **6d** highly reduced the melanin contents (Figure 7).

## Zebrafish toxicity assay

In addition to the depigmenting capacity, other factors are also important in selecting the lead compound for skin whitening and related disorders. For that purpose, additional in vivo zebrafish toxicity was also performed. In recent years, zebrafish has emerged as an important tool for early screening of toxicity of drugs. Acute toxicity is determined by treating the larvae after 48 hpf with 10, 20 and 50 μM of inhibitor **6d**, and fish were examined after 3 days of treatment by staining with acridine orange (Figure 8). The larvae developed into


zebrafish normally without any evidence of apoptotic deformities. This absence of acute toxicity was encouraging for safer drug development. Importantly, no death was recorded in any treatment.



**Figure 7** Inhibitory effects of **6d** and kojic acid on melanin contents.

**Notes:** Zebrafish embryos were treated with 50 μM of **6d** and kojic acid. After homogenation and centrifugation, pellets were prepared and dissolved with 1 N NaOH at 100°C, and absorbances were recorded at 405 nm and compared with synthetic melanin. Values are expressed as % of control. \* $P < 0.05$ ; \*\*\* $P < 0.001$ .





**Figure 8** Zebrafish embryos (48 hpf) were treated with 10, 20 and 50  $\mu\text{M}$  of **6d**. **Notes:** Normal development was observed after acridine orange staining. Some key features were labeled for reference. a, eyes; b, otic capsule; c, heart; d, yolk; e, melanocytes.

**Abbreviation:** hpf, hours post-fertilization.

## Computational studies

### Structural assessment of target protein

Mushroom tyrosinase is a class of oxidoreductase copper-containing protein that comprises 391 amino acids. The structure architecture of mushroom tyrosinase showed that it consists of 39%  $\alpha$ -helices (154 residues), 14%  $\beta$ -sheets (57 residues) and 46% coils (180 residues). The crystal structure showed its resolution 2.78Å, R-value 0.238 and unit cell crystal dimensions such as length and angles of coordinates. The unit cell length values were observed for  $a=103.84$ ,  $b=104.82$  and  $c=119.36$  with angles  $90^\circ$ ,  $110.45^\circ$  and  $90^\circ$  for all  $\alpha$ ,  $\beta$  and  $\gamma$  dimensions, respectively. The Ramachandran plots and values indicated that 95.9% of protein residues were present in favored region and 100.0% residues were lie in allowed region. The Ramachandran graph values showed a good accuracy of phi ( $\phi$ ) and psi ( $\psi$ ) angles among the coordinates of receptor, and most of residues were plunged in acceptable region.

### Chemo-informatics properties and Lipinski's RO5

The predicted chemo-informatics properties such as molecular weight (g/mol), molar volume ( $\text{Å}^3$ ) and polar surface area (PSA) were evaluated by computational tools. The literature

study established a standard value for molecular weight (160–480 g/mol) and PSA (x).<sup>52</sup> Results showed that all the predicted values of synthesized compounds **4a–e** and **6a–e** were comparable with standard values. The obtained drug score is very important for various properties such as physicochemical, pharmacokinetics and pharmacodynamics of chemical compound. Higher drug scores mean good drug characteristics.<sup>53</sup> The drug scores obtained emphasize that all the synthesized amides **4a–e** and **6a–e** exhibited drug-like behavior. The highest and lowest drug scores of both **4c** and **6a** are 1.41 and 0.35, respectively. Moreover, RO5 did not explain anything about the specific chemistry or structural features of the drugs or non-drugs. The computational results showed that all the synthesized compounds possessed  $<10$  HBA,  $<5$  HBD and  $<5.0$  Log  $P$ -values, which significantly justified its drug-like behavior. Moreover, their molecular weight was also  $<500$  g/mol, which also justified the compounds' better drug-like behavior. Rule of 5 indicates that molecules with poor absorption are more likely to have more than 5 HBD, MWT over 500, Log  $P$  over 5 and more than 10 HBA. However, there are plenty of examples that explain RO5 violation among the existing drugs.<sup>54</sup> In summary, the values obtained justify the significance of the synthesized compounds as good candidate molecules (Table 4).

### Molecular docking analyses

The docked complexes of all amide derivatives **4a–e** and **6a–e** were analyzed on the basis of lowest binding energy values (kcal/mol) and hydrogen/hydrophobic bonding analyses. Results showed that **6d** was the most active compound with best binding energy value ( $-7.90$  kcal/mol) compared to other derivatives. The docking pose was selected on the basis of energy value and interaction patterns of ligand within the active region of the target protein. The conformational position within the active region of the target protein was

**Table 4** Chemo-informatics evaluation of the synthesized compounds

Properties	4a	4b	4c	4d	4e	6a	6b	6c	6d	6e
MW	327	327	343	343	343	337	353	353	369	371
HBA	4	4	5	5	5	3	4	4	5	3
HBD	2	2	3	3	3	1	2	2	3	1
Log $P$	2.8	3.8	3.4	3.4	3.5	4.8	4.4	4.5	4.1	4.5
PSA	61	61	77	76	78	42	59	60	77	42
MV	328	328	339	341	339	361	372	372	382	378
Drug score	1.09	1.11	1.41	1.30	0.85	0.35	0.42	0.68	0.69	0.83
RO5	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

**Abbreviations:** MW, molecular weight (g/mol); HBA, hydrogen bond acceptor; HBD, hydrogen bond donor; Log  $P$ , lipophilicity of partition coefficient; PSA, polar surface area; MV, molar volume ( $\text{Å}^3$ ); RO5, rule of five.

confirmed by superimposition. The docked complex of **6d** was superimposed against the experimental crystal structure of tyrosinase. Results showed that the ligand **6d** actively bound within the binding pocket of the target protein. The docking energy values of all the docking complexes were calculated by the following equation:

$$\Delta G_{\text{binding}} = \Delta G_{\text{gauss}} + \Delta G_{\text{repulsion}} + \Delta G_{\text{hbond}} + \Delta G_{\text{hydrophobic}} + \Delta G_{\text{tors}}$$

where,

$\Delta G_{\text{gauss}}$ : attractive term for the dispersion of two Gaussian functions,


$\Delta G_{\text{repulsion}}$ : square of the distance if closer than a threshold value,

$\Delta G_{\text{hbond}}$ : ramp function – also used for interactions with metal ions,

$\Delta G_{\text{hydrophobic}}$ : ramp function,

$\Delta G_{\text{tors}}$ : proportional to the number of rotatable bonds.

Docking results justified that the synthesized amides **6b**, **6d** and **6e** exhibited good binding energy values (−8.0, −7.9 and −7.9 kcal/mol, respectively). The standard error for Autodock is reported as 2.5 kcal/mol. Though the basic nucleus of all the synthesized compounds was the same, most of the ligands possessed efficient energy values and did not show any significant difference in energy fluctuations. The comparative binding energies of all the docking complexes are presented in Figure 9.



**Figure 9** Docking energies of the synthesized amide derivatives **4a–e** and **6a–e** calculated using PyRx.


This comparative analysis shows that **6d** directly interacts with the active residues of the target protein. The structure–activity relationship analysis showed that **6d** formed two hydrogen bonds and one  $\pi$ – $\pi$  interaction at specific residues His244, Met280 and His363 of target protein. The ester carbonyl oxygen in **6d** interacts with His244, while benzyl oxygen moiety interacts with Met280 and forms strong hydrogen bonds with lengths of 1.98Å and 2.87Å, respectively. Another  $\pi$ – $\pi$  interaction between the benzene and metal-bonded His363 residue was formed with a bond length of 4.07Å. The literature study also justified that these interacted residues are significant in the downstream signaling pathways.<sup>55</sup> The binding interactions of **6d** with the amino acids of the target protein are presented in Figure 10, and the 2D-generated docking complexes of all ligands are presented in Figures S3–S11.

## MD simulations analyses

### Root mean square deviation and fluctuations of target protein

To evaluate the mushroom tyrosinase flexibility and overall stability of docking complexes, we executed time-dependent MD simulation at 15 ns using Gromacs 4.5.4. The residual deviations and fluctuation of the complexes **6a** and **6d** were determined by root mean square deviation and fluctuation (RMSD/F) graphs generated by Xmgrace software. Both docked complexes were run separately in simulation to check the fluctuating differences of the residual backbone of the target protein. An increasing trend was observed in the graph lines of both complexes with an RMSD value of 0–0.2 nm at time 0–1,250 ps, after which both complexes showed slight fluctuations and attained a little stability from 1,250 to 5,000 ps with a constant RMSD value of 0.2 nm. From 5,000 to 75,000 ps, **6d** graph line remained steadily constant and showed no fluctuations, whereas **6a** graph line showed an increasing trend and depicted higher RMSD value of 0.25 nm. Comparative analysis showed that **6d** had more stable behavior compared to **6a** complex. These results justified that the binding of **6d** toward the target protein is more stable compared to all other **6a** derivative (Figure 11).

The overall RMSD results justified that **6d** did not change the conformational symmetry of the target protein compared to **6a**. The RMSF results also reflected that both C- and N-terminal lobes of mushroom tyrosinase are fluctuated throughout the simulation period. Comparative analysis justified that **6d** is more stable and less fluctuated throughout the simulation period compared to **6a** (Figure 12). MD simulation graphs showed stable behaviors of **6d** docked complex



**Figure 10** Docking interactions between **6d** and target protein.

**Notes:** (A) The **6d** docking complex with ligand is in blue color and embedded functional groups such as oxygen and amino are highlighted in red and dark blue colors, respectively. The protein structure is represented in purple color while interior helices are depicted in brown color. (B) Six copper-interacted residues lie within the active region of target protein and are represented in purple color. (C) The binding pocket of target protein in surface format is represented in dark purple color with conformational position of ligand. (D) Closer view of docking interaction. The active binding site amino acids are highlighted in brown color. Two copper ions are also represented in gray color. Two hydrogen bonds and one  $\pi$ - $\pi$  interaction were observed between **6d** and receptor amino acids such as His244, Met280 and His363 with bonding distances 1.98, 2.87, and 4.07Å, respectively. Interacted residues are in red color labels.


throughout MD trajectories thus increasing the efficacy of docking results.

The compactness of the target protein was measured by radius of gyration (Rg). The results obtained for both **6a** and **6d** showed that the Rg value underwent a little fluctuation between 2 and 2.03 nm throughout the simulation time 0–15 ns. These results justified that the residual backbone and folding of the receptor protein **6d** was comparatively stable compared with **6a**. The Rg values and graph lines of **6a** and **6d** are shown in Figure 13. The solvent accessible

surface area and dihedral pattern (Chi) of the target protein are given in Figures S12 and S13.

## Conclusion

Hydroxylated amide derivatives **4a–e** and **6a–e** were synthesized following simple reaction routes with excellent yields as melanogenesis inhibitors. The in vitro, in vivo and computational studies proved that compound **6d** is a highly potent melanogenesis inhibitor compared to standard kojic acid. Among the synthesized amides, **6d** showed excellent




**Figure 11** RMSD graph of **6a** and **6d** at 15 ns.

**Note:** The graph lines with purple and green colors represent **6a** and **6d** complexes, respectively.

**Abbreviation:** RMSD, root mean square deviation.


mushroom tyrosinase inhibitory activity ( $IC_{50}$  0.15  $\mu$ M) compared to standard kojic acid ( $IC_{50}$  16.69  $\mu$ M). The enzyme inhibition kinetics determined by Lineweaver–Burk plots showed that compounds **4c** and **6d** exhibited non-competitive inhibition, while **6a** and **6b** exhibited mixed-type inhibitions. The kinetic mechanism further revealed that compound **6d** formed irreversible complex with the target enzyme tyrosinase. The  $K_i$  values of compounds **4c**, **6a**, **6b** and **6d** were 0.188  $\mu$ M, 0.84  $\mu$ M, 2.20  $\mu$ M and 0.217  $\mu$ M, which shows that compound **6d** possessed stronger binding capacity. The same compound **6d** also showed an inhibitory activity of 91.9% on human tyrosinase. The in vivo cytotoxicity evaluation of **6d** in zebrafish embryos showed that it is non-toxic to zebrafish. The melanin depigmentation



**Figure 12** RMSF graph of **6a** and **6d** at 15 ns.

**Note:** The graph lines with purple and green colors represent **6a** and **6d** complexes, respectively.

**Abbreviation:** RMSF, root mean square fluctuation.



**Figure 13** Radius of gyration ( $R_g$ ) graphs of **6a** and **6d**: bound and unbound formats.

**Note:** The graph lines with green and purple represent the bound and unbound target protein, respectively.

assay in zebrafish indicated that compound **6d** had a greater potential in decreasing melanin contents compared to kojic acid at same concentration. The computational studies also supported the wet lab findings as the compound **6d** exhibited highest binding affinity with the target protein (PDBID: 2Y9X) with a binding energy value of  $-7.90$  kcal/mol. The MD simulation studies also proved that amide **6d** formed the most stable complex with tyrosinase. Based upon our in vitro, in vivo and computational studies, we propose that compound **6d** is a promising candidate for the development of safe cosmetic agent.

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. *Trends Mol Med*. 2006;12(9):406–414.
- Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. *Nature*. 2007;445(7130):843–850.
- Raj D, Brash DE, Grossman D. Keratinocyte apoptosis in epidermal development and disease. *J Invest Dermatol*. 2006;126(2):243–257.
- Sánchez-Ferrer A, Rodríguez-López JN, García-Cánovas F, García-Carmona F. Tyrosinase: a comprehensive review of its mechanism. *Biochem Biophys Acta*. 1995;1247(1):1–11.
- Van Holde KE, Miller KI, Decker H. Hemocyanins and invertebrate evolution. *J Biol Chem*. 2001;276(19):15563–15566.
- Solminski A, Constantino R. L-tyrosine induces tyrosinase expression via a post transcriptional mechanism. *Experientia*. 1991;47(7):721–724.
- Solminski A, Constantino R. Molecular mechanism of tyrosinase regulation by L-dopa in hamster melanoma cells. *Life Sci*. 1991;48(21):2075–2079.
- Solminski A, Paus R. Are L-tyrosine and L-dopa hormone-like bioregulators? *J Theor Biol*. 1990;143(1):123–138.



9. Prota G. *Melanins and Melanogenesis*. New York: Academic Press Inc; 1992.
10. Prota G. The chemistry of melanins and related metabolites. *Fortsch Chem Organ Natur*. 1995;64:93–148.
11. Kadekaro AL, Kanto H, Kavanagh R, Abdel-Malek ZA. Significance of the melanocortin 1 receptor in regulating human melanocytes pigmentation, proliferation and survival. *Ann N Y Acad Sci*. 2003;994:359–365.
12. Petit L, Pierard GE. Skin-lightening products revisited. *Int J Cosmet Sci*. 2003;25(4):169–181.
13. Riley PA. Melanogenesis and melanoma. *Pigment Cell Res*. 2003;16(5):548–552.
14. Uong A, Zon LI. Melanocytes in development and cancer. *J Cell Physiol*. 2010;222(1):38–41.
15. Yamaguchi Y, Hearing VJ. Melanocytes and their diseases. *Cold Spring Harb Perspect Med*. 2014;4(5):pii:a017046.
16. Lynde CB, Kraft JN, Lynde CW. Topical treatments for melasma and postinflammatory hyperpigmentation. *Skin Therapy Lett*. 2006;11(9):1–6.
17. Asanuma M, Miyazaki I, Ogawa N. Dopamine- or L-DOPA induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. *Neurotox Res*. 2003;5(3):165–176.
18. Zhu YJ, Zhou HT, Hu YH, et al. Antityrosinase and antimicrobial activities of 2-phenylethanol, 2-phenylacetaldehyde and 2-phenylacetic acid. *Food Chem*. 2011;124(1):298–302.
19. Xu Y, Stokes AH, Roskoski R Jr, Vrana KE. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. *J Neurosci Res*. 1998;54(5):691–697.
20. Menezes JC, Kamat SP, Cavaleiro JA, Gaspar A, Garrido J, Borges F. Synthesis and antioxidant activity of long chain alkyl hydroxycinnamates. *Eur J Med Chem*. 2011;46(2):773–777.
21. Miliovisky M, Svinjarov I, Mitrev Y, et al. A novel one-pot synthesis and preliminary biological activity evaluation of cis-restricted polyhydroxy stilbenes incorporating protocatechuic acid and cinnamic acid fragments. *Eur J Med Chem*. 2013;66:185–192.
22. Liu XD, Huang H, Chen QX. Studies on inhibitory effects of benzoic acid on mushroom tyrosinase. *J Xiamen Univ Natur Sci*. 2003;42(1):102–106.
23. Chen QX, Song KK, Qiu L, Liu XD, Huang H, Guo HY. Inhibitory effects on mushroom tyrosinase by p-alkoxybenzoic acids. *Food Chem*. 2005;91(2):269–274.
24. Takahashi T, Miyazawa M. Synthesis and structure–activity relationships of phenylpropanoid amides of serotonin on tyrosinase inhibition. *Bioorg Med Chem Lett*. 2011;21(7):1983–1986.
25. Ashraf Z, Rafiq M, Seo SY, Babar MM, Zaidi NSS. Design, synthesis and bioevaluation of novel umbelliferone analogues as potential mushroom tyrosinase inhibitors. *J Enzyme Inhib Med Chem*. 2015;30(6):874–883.
26. Kraunsoe JA, Claridge TD, Lowe G. Inhibition of human leukocyte and porcine pancreatic elastase by homologues of bovine pancreatic trypsin inhibitor. *Biochemistry*. 1996;35(28):9090–9096.
27. Kim SJ, Sancheti SA, Sancheti SS, Um BH, Yu SM, Seo SY. Effect of 1, 2, 3, 4, 6-penta-O-galloyl-beta-D-glucose on elastase and hyaluronidase activities and its type II collagen expression. *Acta Pol Pharm*. 2010;67(2):145–150.
28. Reddy CVK, Sreeramulu D, Raghunath M. Antioxidant activity of fresh and dry fruits commonly consumed in India. *Food Res Int*. 2010;43(1):285–288.
29. Ashraf Z, Rafiq M, Seo SY, Babar MM, Zaidi NSS. Synthesis, kinetic mechanism and docking studies of vanillin derivatives as inhibitors of mushroom tyrosinase. *Bioorg Med Chem*. 2015;23(17):5870–5880.
30. Ashraf Z, Rafiq M, Seo SY, Kwon KS, Babar MM, Zaidi NSS. Kinetic and in silico studies of novel hydroxy-based thymol analogues as inhibitors of mushroom tyrosinase. *Eur J Med Chem*. 2015;98:203–211.
31. Sugimoto K, Nishimura T, Nomura K, Sugimoto K, Kuriki T. Syntheses of arbutin- $\alpha$ -glycosides and a comparison of their inhibitory effects with those of  $\alpha$ -arbutin and arbutin on human tyrosinase. *Chem Pharm Bull (Tokyo)*. 2003;51(7):798–801.
32. Funayama M, Nishino T, Hirota A, Murao S, Takenishi S, Nakano H. Enzymatic synthesis of (+) catechin- $\alpha$ -glucoside and its effect on tyrosinase activity. *Biosci Biotech Biochem*. 1993;57(10):1666–1669.
33. Choi T-Y, Kim J-H, Ko DH, et al. Zebrafish as a new model for phenotype-based screening of melanogenic regulatory compounds. *Pigment Cell Res*. 2007;20(2):120–127.
34. Hsu KD, Chen HJ, Wang CS, et al. Extract of Ganoderma formosanum mycelium as a highly potent tyrosinase inhibitor. *Sci Rep*. 2016;6:32854.
35. Baek SH, Lee SH. Sesamol decreases melanin biosynthesis in melanocyte cells and zebrafish: possible involvement of MITF via the intracellular cAMP and p38/JNK signalling pathways. *Exp Dermatol*. 2015;24(10):761–766.
36. Thompson MJ, Louth JC, Ferrara S, et al. Discovery of 6-substituted indole-3-glyoxylamides as lead antiprion agents with enhanced cell line activity, improved microsomal stability and low toxicity. *Eur J Med Chem*. 2011;46(9):4125–4132.
37. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera – a visualization system for exploratory research and analysis. *J Comput Chem*. 2006;25(13):1605–1612.
38. Lovell SC, Davis IW, Arendall WB 3rd, et al. Structure validation by Calpha geometry: phi, psi and Cbeta deviation. *Proteins*. 2002;50(3):437–450.
39. Chen VB, Arendall WB 3rd, Headd JJ, et al. MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr D Biol Crystallogr*. 2010;66(Pt 1):12–21.
40. Discovery Studio. Version 2.1. San Diego, CA: Accelrys; 2008. Available from: <http://accelrys.com/products/collaborative-science/biovia-discovery-studio/requirements/technical-requirements-450.html>. Accessed June 1, 2017.
41. Willard L, Ranjan A, Zhang H, et al. VADAR: a web server for quantitative evaluation of protein structure quality. *Nucleic Acids Res*. 2003;31(13):3316–3319.
42. Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. *Methods Mol Biol*. 2015;1263:243–250.
43. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. *Protein Eng*. 1996;8(2):127–134.
44. Pronk S, Pall S, Schulz R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. *Bioinformatics*. 2013;29(7):845–854.
45. Chiu SW, Pandit SA, Scott HL, Jakobsson E. An improved united atom force field for simulation of mixed lipid bilayers. *J Phys Chem B*. 2009;113(9):2748–2763.
46. Schüttelkopf AW, van Aalten DMF. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. *Acta Crystallogr D Biol Crystallogr*. 2004;60(Pt 8):1355–1363.
47. Wang H, Dommert F, Holm C. Optimizing working parameters of the smooth particle mesh Ewald algorithm in terms of accuracy and efficiency. *J Chem Phys*. 2010;133(3):034117.
48. Amiri S, Sansom MS, Biggin PC. Molecular dynamics studies of AChBP with nicotine and carbamylcholine: the role of water in the binding pocket. *Protein Eng Des Sel*. 2007;20(7):353–359.
49. Ashraf Z, Alamgeer, Rasool R, et al. Synthesis, bioevaluation and molecular dynamic simulation studies of dexibuprofen–antioxidant mutual prodrugs. *Int J Mol Sci*. 2016;17(12):2151.
50. Chen Z, Cai D, Mou D, et al. Design, synthesis and biological evaluation of hydroxy- or methoxy-substituted 5-benzylidene (thio) barbiturates as novel tyrosinase inhibitors. *Bioorg Med Chem*. 2014;22(13):3279–3284.
51. Veldman MB, Lin S. Zebrafish as a developmental model organism for pediatric research. *Pediatr Res*. 2008;64(5):470–476.

52. Kadam RU, Roy N. Recent trends in drug-likeness prediction: a comprehensive review of in silico methods. *Indian J Pharm Sci.* 2007;69: 609–615.
53. Bakht MA, Yar MS, Abdel-Hamid SG, Al-Qasoumi SI, Samad A. Molecular properties prediction, synthesis and antimicrobial activity of some newer oxadiazole derivatives. *Eur J Med Chem.* 2010;45(12): 5862–5869.
54. Tian S, Wang J, Li Y, Li D, Xu L, Hou T. The application of in silico drug-likeness predictions in pharmaceutical research. *Adv Drug Del Rev.* 2015;86:2–10.
55. Chen WC, Tseng TS, Hsiao NW, et al. Discovery of highly potent tyrosinase inhibitor, T1, with significant anti-melanogenesis ability by zebrafish in vivo assay and computational molecular modeling. *Sci Rep.* 2015;5:7995.

### Drug Design, Development and Therapy

Dovepress

### Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>